In June 2023, Merck, known as MSD outside of the United States and Canada, had announced the completion of the Prometheus ...

Agilent Technologies Inc faces a challenging market with a 6-7% revenue decline in the latest quarter. Despite market headwinds, Agilent's CrossLab segment shows resilience with a 4-5% revenue ...

The Agilent 6400 Series Triple Quadrupole LC/MS Systems are the proven choice for your quantitative applications in pharmaceutical ADME/DMPK studies, biomarker validation, clinical research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Credit: Jawahar Swaminathan and MSD staff at the European Bioinformatics Institute ... Adaptimmune has partnered with the US-based pharmaceutical company Agilent Technologies to develop, manufacture ...

Solid-phase extraction (SPE) is the gold standard for sample preparation in chromatographic analysis. It is used to capture, clean, and concentrate samples while removing interfering compounds ...

MSD’s Winrevair has been approved to treat pulmonary arterial hypertension (PAH), a disorder which is caused by high blood pressure in the lungs. Credits: MMD Creative/Shutterstock.com The European ...

Agilent Technologies focuses on growing biopharma, PFAS testing, and advanced materials for semiconductors. Recent acquisitions and divestitures show mixed results, with potential for ...

Bruker Corporation has delivered 20% annual returns for 15 years but has seen a 34% drop in share price from all-time highs. Bruker's business model includes advanced equipment for imaging ...

Aug 21 (Reuters) - Agilent Technologies (A.N), opens new tab on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and ...

Revenue of $1.58 billion, down 5.6% reported and 4.4% core (1) from the third quarter of 2023. GAAP net income of $282 million; earnings per share (EPS) of $0.97, up 155% from the third quarter of ...